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The  pathogenicity  and  invasiveness of  group  A  streptococci for man,  as 
well as for laboratory animals, have been shown to be closely correlated with 
the presence of the M protein; conflicting evidence, however, has been obtained 
by several groups of investigators with  regard  to  the  r61e of the  hyalttronic 
acid capsule in the manifestation of virulence of these microorganisms. 
A number of studies have been carried out in an effort to ascertain the effect of 
these substances on the pathogenesis of streptococcal infections.  Several workers 
have studied  the protective action in mice,  infected with group A streptococci, of 
immune  serum  containing  antibodies  directed  against  the  M  substance.  Others 
have studied the protective effect of hydrolyzing the capsular material with an enzyme, 
hyaluronidase.  As a result of the antibody studies the M substance has been shown 
to be essential for the exhibition of virulence,  since anti-M antibodies provide active 
and passive protection of mice against infection  with virulent streptococci of homol- 
ogous type (1-3).  On the other hand, the relation of the hyaluronic acid capsule to 
mouse virulence is not so well defined.  While Hirst (4) was able to protect mice in- 
fected with encapsulated group C  streptococci by treatment with leech extract con- 
t~ining  hyaluronidase, he was not able to protect mice infected  with group A  strep- 
tococci;  although the capsular materials of both these groups of  streptococci have 
been shown  by Scastone  (5)  to  be  chemically similar.  Blundell  (6)  obtained  no 
definite protection against group A streptococcus infections in mice with crude bovine 
testicular hyaluronidase but observed a  greater mean  survival time; and McClcan 
(7), using enzyme from a similar source,  failed  to obtain protection in mice infected 
with either group A or group C streptococci. 
However, Kass and Scastone (8),  who recently  succeeded  in protecting mice to 
some extent against infection  with group A  streptococci by usir~g bovine testicular 
hyaluronidase, ascribed the failure of earlier workers to the use of insufficient amounts 
of enzyme and  to too long an interval between  injections.  Both of these factors 
tended to permit the  streptococci to  regenerate their  capsules  in the infected host. 
In view of  these  conflicting  reports  as  to  the  protective  effect of  hyalu- 
ronidase, it seemed desirable to reinvestigate this problem and to attempt to 
determine the relative significance of the hyaluronic acid capsule and the M 
protein in the virulence of group A  streptococci. 
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For  this purpose, 5 strains of group A streptococci were  selected, each of which 
was available in a glossy and matt form.  The glossy variants were mouse-avirulent 
and produced little or no M protein; the matt variants were made mouse-virulent  by 
animal passage and elaborated large amounts of the M substance.  Both variants of 
each of the 5 strains were morphologically well encapsulated. 
As  criteria of  virulence, two  different and distinct systems were employed: (1) 
an in vitro test involving  the capacity of the streptococcal cells to resist phagocytosis 
by leukocytes in human blood; and (2) an in vivo test involving  the ability of group A 
streptococci to kill mice following intraperitoneal inoculation.  The protective effect 
of anti-M serum and an enzyme, hyaluronidase, which hydrolyzes the capsular ma- 
terial, was also studied in the in vivo system against group A streptococcal infections 
in mice. 
Materials and Methods 
Strains of Hemolytic Streptococci.--The 5 strains  of group  A streptococci were selected 
because each represented a different serological type, each had a glossy and a matt variant, 
and both variants were capable of producing good capsules under appropriate conditions. 
Griffith's (9) original type strains were used for types 1, 3, and 19.  They were designated 
by him as strains SF 130/2, Lewis opaque 47T, and SF 73/4 and catalogued in this laboratory 
as T1, T3, and T19 respectively.  Strain NY5 was isolated by Stevens and Dochez (10) and 
used by Griffith as the representative type 10, now designated type 12.  Strain $23, type 14, 
was isolated from the throat of a patient with lobar  pneumonia (11).  The group C strain, 
designated D181 in this  laboratory,  was isolated by Seastone (5)  from a  guinea pig with 
chronic lymphadenitis and referred to as strain 4. 
Media for Preparation of Cultures.--Todd-Hewitt filtered broth was the most favorable 
of several media tried for production of well formed capsules (2).  Well encapsulated strep- 
tococci in the logarithmic phase of growth were prepared by adding to 9 parts of this medium 
one part of an actively growing 12 hour culture and incubating  in a water bath at 37°C. for 
3 to 4 hours.  Large capsules (Figs. 1-10) were demonstrable by the moist India ink method 
(12) in both variants of all the strains studied.  The cultures were standardized turbidimet- 
rically at a wave length of 520 m# before each experiment, and this was checked by pouring 
rabbit blood agar plates to estimate the bacterial population. 
The methods of preparing the antisera and M extracts  (13, 14), as well as the techniques 
used in the precipitin and bacteriostatic tests (15, 16), have previously been described.  The 
method for preparing crude bovine testicular extract  containing hyaluronidase was that of 
Kass and Seastone (8).  For the mouse virulence and protection  experiments, mice of the 
Rockefeller Institute strain, weighing 15 to 20 gin., were employed. 
EXPEI~IMI~NTAL 
The Relationship between the Production of M  Protein and Mouse  Virulence 
of Group A  Streptococci.--Experiments were devised to determine the compara- 
tive capacities of the equally well encapsulated glossy and matt variants to 
produce the M  substance and to kill mice.  From 45 cc. of actively growing 
3 hour broth cultures of the encapsulated variants, after a sample was removed 
for  the  mouse  virulence tests,  crude  M  extracts  were  prepared.  Twofold 
serial dilutions of these extracts were tested by the capillary precipitin method 
(15)  with homologous, absorbed anti-M serum,  as recorded  in Table  I.  A smh~EY ROTIIBAKD  327 
distinct difference in the amount of the M  substance elaborated by the glossy 
and matt variants of each pair of strains is  apparent.  Dilutions  as high  as 
1:32 of the extracts of the matt variants showed positive reactions, whereas 
the undiluted extracts of the glossy variants  gave only weak or no precipitin 
reactions. 
For the mouse virulence tests,  tenfold serial dilutions were prepared from 
samples  removed from the  cultures tested for M  substance.  The results of 
these  tests  are  summarized  in  Table  II.  A  marked  difference  in  mouse 
virulence between the glossy and matt strains was  found in spite of the fact 
TABLE I 
Production of Type-Specific M Antigen by Encaps.ulated Variants of Group A Streptococci 
Precipitin Reactions with M Extracts and Homologous Antisera 
Variant. ............  Glossy  Matt 
Strain  ..............  T1  T3  NY5  S~  TI9  T1  T3  NY5  S~  TI9 
Serological type  .....  1  3  12  14  19  1  3  12  14  19 
Titration of M 
extract 
1:1 
1:2 
1:4 
1:8 
1:16 
1:32 
1:64 
-4-  4-  4-  0 
0  0  :t:  0  0 
0  0  0  0  0 
0  0  0  0  0 
0  0  0  0  0 
0  0  0  0  0 
0  0  0  0  0 
+++  +++±  +++  +++  +++ 
+++  ++  +++  +++  +++ 
++  ++  +++  ++4.  +++ 
++  ++  ++4.  ++4.  +++ 
++  +4.  ++~  ++±  ++ 
+  ±  ~  +  + 
0  0  0  0  0 
In titration  of M antigen, degree of precipitation is indicated by a ++++  to 4- scale; 
0 represents no precipitation. 
that  each variant elaborated equally good hyaluronic acid capsules.  All of 
the  encapsulated  glossy  variants  were  relatively  mouse-avirulent;  the  en- 
capsulated matt variants were highly virulent, as indicated by death in 3  to 
4 days occurring in mice infected with 10  -8 cc. of culture, containing 2 to 3 
microorganisms.  Examination  of  selected  mice  that  died  all  revealed  en- 
capsulated streptococci in the peritoneal exudate or heart blood.  In addi- 
tional  experiments  it  was  shown  that  polymorphonuclear neutrophils  and 
monocytes in the exudate, obtained from the peritoneal cavity of mice inocu- 
lated  with  the  encapsulated  glossy variants,  were actively phagocyting the 
streptococci, but only rarely were the encapsulated matt variants taken up by 
the phagocytic leukocytes. 
While  these  experiments  clearly demonstrate  the  relationship  of  the  M 
protein  to  mouse virulence,  they do  not  bring  out  any  evidence  that  the 
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TABLE  II 
Mouse Virulence of Encapsulated Variants of Group A S~¢eptococci 
V~nt  ...........................  Olo~y  Matt 
Strain .............................  T1  T3  N'Y5  S23  TI9  TI  T3  NY$  $28  TI9 
Serologicsl type  ....................  1  3  12  14  19  I  3  12  14  19 
Dose 
66. 
10-* 
I0-' 
I0-: 
I0-~ 
10-6 
lO--e 
I0-' 
10-~ 
D1  D1  DI  D1  D1 
I)i  D1  D2  D1  D1 
D2  D1  D2  D2  D1 
S  D2  S  D1  D1 
S  D2  S  D2  D1 
S  S  S  S  S 
S  S  S  S  S 
S  S  S  S  S 
S  S  S  S  S 
S  S  S  S  S 
S  S  S  S  S 
S  S  S  S  S 
S  S  S  S  S 
S  S  S  S  S 
S  S  S  S  S 
S  S  S  S  S 
S  S  S  S  S 
S  S  S  S  S 
S  S  S  S  S 
S  S  S  S  S 
S  S  S  S  S 
S  S  S  S  S 
S  S  S  S  S 
S  S  S  S  S 
D1  D1  DI  D1  D1 
D1  D1  D1  D1  D1 
D1  D1  D1  D1  D1 
D1  D1  D1  D1  DI 
D1  D1  D1  D1  DI 
D1  D1  D1  DI  D1 
D1  D1  D1  D1  D1 
D1  D1  D1  D1  D1 
D1  D1  D1  D1  DI 
D1  D1  D1  D1  DI 
D1  D1  D1  D1  D2 
D1  DI  D1  D1  D2 
D1  D1  D2  D1  D2 
D1  D1  D2  D2  D2 
D1  D1  D2  D2  D2 
D2  D2  D2  D2  D2 
D2  D2  D2  D2  D3 
D3  D2  D2  D2  D3 
D2  D2  D2  D2  D3 
D3  D2  D2  D3  D3 
D3  D3  D3  D2  S 
D3  D3  D3  D3  D3 
D3  D4  D3  D3  D3 
D3  D4  D3  S  S 
s  indicates survival of one mouse/or at least 2 weeks. 
D with numeral indicates death of one mouse within that number of days. 
streptococci for mice.  Subsequent  studies, however, with special techniques, 
revealed  that  the  capsular  material  does  have  some  influence on  the  patho- 
genicity of these bacteria. 
Antiphagocytic  Effect  of  tke  M  Substance  and  Hyaturonic  Acid  Capsule. 
In  order  to  analyze  the  method  of  destruction  of  these  streptococci  in  the sm~Y  ~oTm3A.V,.o  329 
animal body, an in ~itro test was employed, which involved phagocytosis of the 
streptococci by the leukocytes of normal human  blood.  Experiments  with 
mouse and human blood revealed that the streptococci were phagocyted in the 
blood of both species.  Although it was theoretically preferable to use mouse 
blood as a test system since mouse virulence was being studied, it was found 
necessary to employ human blood because of the difficulty of obtaining suf- 
ficient quantities of blood from mice.  Furthermore,  the use of human blood 
was in itself of interest because of the relationship of the virulence of group A 
streptococci to human infection.  Therefore, normal children's blood, which 
contains no  detectable natural  opsonins for these  microorganisms,  was  em- 
ployed. 
The crude bovine testicular extract used in all  the  experiments as a source 
of hyaluronidase was found, in  agreement with earlier workers, not to impair 
the phagocytic function  of the leukocytes.  Moreover, this enzyme prevents 
the formation of capsules of group A  and group  C  streptococci during their 
growth cycle (Figs.  11 and 12).  The question arose as to whether this crude 
tissue extract might contain proteolytic enzyme capable  of digesting  the M 
antigen of the streptococcal cell  Experiments were devised to test this pos- 
sibility. 
Washed group A streptococcal  cells, strain $23, matt, type 14, from 500 cc. of Todd-Hewitt 
broth culture, were suspended in 4 cc. of physiological  saline and heat-killed at 56°C. for 30 
minutes.  To one-half of these cdis was added 2 cc. of crude bovine testicular extract con- 
raining 200 viscosity-reducing  units of hyaluronidase; to the other half was added the same 
amount of extract inactivated by heating for 30 minutes at 60°C.  After incubation of these 
mixtures at 37°C. for 18 hours, M extracts were prepared, diluted in a twofold  serial manner, 
and tested against homologous  antiserum. 
Each test sample revealed approximately the same amount of M  substance 
on titration.  The same  experiment was  repeated with  the  addition  to  the 
testicular extract of a reducing substance, thioglycollic acid, in a final concen- 
tration of 0.01  M,  in  order  to  activate  any  previously inactive proteolytic 
enzyme which might be present.  Again the M  titres  obtained  were  essen- 
tially the same in the two systems.  In an additional experiment, using M 
substance in solution, samples of M  extract were mixed with an equal volume 
of testicular extract containing 20 viscosity-reducing units  of hyaluronidase 
or with heat-inactivated testicular extract, and incubated at 37°C. for 18 hours. 
Twofold serial dilutions of the mixtures were made and tested against homol- 
ogous antiserum.  No  evidence of digestion of M  substance  was  obtgined. 
Further studies also  revealed that the crude bovine  testicular extract failed 
to digest gelatin or casein.  Since the testicular hyaluronidase employed did 
not digest the M  protein on the streptococcal cell or in solution, this extract 
was considered suitable as a source of hyaluronidase free of proteolytic enzyme. 
To determine the antiphagocytic effect of the M  substance and hyaluronic 
acid capsule, opsonic index experiments were performed. 330  GROUP  A  STREPTOCOCCUS  INIeECTIONS 
Suspensions of well encapsulated,  3 hour cultures of the glossy and matt variants were 
turbidimetrically  standardized,  and blood agar plates were poured to estimate the bacteria! 
count.  To each of a series of tubes were added 0.05 cc. of culture  dilution containing ap- 
proximately 1,000,000 streptococci, 0.25 cc. of fresh, heparinized, human blood, and 0.05 cc. 
of hya!uronidase (10 viscosity-reducing units),  type-specific anti-M serum, or saline.  After 
20 minutes in a  rotating machine at 37°C., the tubes were plunged into ice water to stop 
phagocytosis; and smears were made and stained with Wright-Giemsa solution.  The per cent 
of active leukocytes and the number of cocci ingested by 100 polymorphonuclear neutrophils 
were determined. 
TABLE III 
Phagocytic Action of Normal Human Blood on Capsulaled and Deeapsulated Variants of 
Group A Streptococd 
Variant....__  "'~1 
Strain .........  I 
 o'o i.:tl.  ....  , 
Glossy 
T1  T3  NY5  $23  T19 
1  3  12  14  19 
Matt 
T1  "1"3  N'Y5  S23  TI9  TI 
1  3  12  14  1 
None 
I"3  NY$  823  T19 
3  12  14  19 
None  Anti-M Serum 
Capsulated streptococci 
No.  of  cocci I 
phagocyted 
by 100 leuko-  I 
cytes ........ [ 
Percentage  of ] 
active leuko- 
cites ........ 
1596  1920 1664 1560 2060 
97  96  92  84  94 
39  26  45  46 
6  2  6  6 
40  1210  1550 1310 1240 1700 
10  93  90  94  90  89 
Streptococci decapsulated with hyaluronidase 
No.  of  cocci ] 
phagocyted  [ 
by lOO lenko-  t 
cytes ........ ] 
Percentage  of I 
active leuko- 
cytes ........ 
2767  2355 2242 2210  2646 
99  93  93  92  96 
158  210  210  270  315 
12  24  20  12  25 
2340  2410  1780 1700 2710 
95  97  95  91  93 
The results of the foregoing experiment  are illustrated  in Table III.  The 
antiphagocytic properties  of the M  substance are shown by the fact that the 
matt, M-producing variants of both capsulated and decapsulated streptococci 
are markedly more resistant to phagocytosls than the glossy non-M-producing 
variants.  On addition  of anti-M  serum  the  encapsulated  matt  variants  be- 
come as susceptible  to phagocytosis as the  encapsulated  glossy variants.  It 
will be noted that when hyaluronidase is added to the  systems, with resulting 
removal  of the  capsules,  more  of  the  streptococci  are  phagocyted  than  in 
comparable systems in which the streptococci remain encapsulated because no 
hyaluronidase is added.  These observations suggest that the hyaluronic acid 
capsule has some antiphagocytic property. smNE,Z  ROTImA~  331 
Photomicrographs of representative fields of smears made in the phagocytic 
experiments  are  shown  for  the  strain  $23,  type  14  system.  It  should  be 
noted that no phagocytosis occurs if M  protein is synthesized by the strepto- 
cocci regardless of whether the capsule is present (Figs. 13 and  14); however, 
it can  be seen (Figs.  15  and  16)  that  phagocytosis of  encapsulated,  non-M- 
containing,  glossy variants does take place, but that the decapsulated  glossy 
variants are phagocyted to a  somewhat greater  extent.  As can be noted in 
Fig. 15, after phagocytosis of encapsulated organisms the capsule is no longer 
visible, which suggested that the leukocytes may contain hyaluronidase capable 
of  digesting  the capsular  material.  However, efforts to isolate this  enzyme 
from large amounts of leukocytes obtained from human blood were unsuccess- 
ful. 
Because the ultimate  fate  of the streptococci  ingested by  the phagocytes 
is  not  shown  by opsonic  index  experiments  such  as  that  just  described,  a 
bacteriostatic test was employed.  By this  method  it has been demonstrated 
that  the  ingested  bacterial  ceils are destroyed by the phagocytic leukocytes 
(16). 
Tenfold serial dilutions were used of a 3 hour broth culture of well encapsulated strepto- 
cocci, ranging from 10  -1 through 10  ~.  In these experiments, 200 to 300 bacterial cells were 
contained in the 10  -e dilutions.  To each of a series of tubes were added 0.05 cc. of culture 
dilution, 0.05 cc. of hyaluronidase (I0 viscosity-reducing  units), saline, or type-specific  anti-M 
serum, and 0.25 ce. of fresh, heparinized, human blood.  After incubation at 37°C. in a rotator 
for 3 hours, samples from each mixture were removed and streaked on rabbit blood agar 
plates.  The resulting growth after 18 to 24 hours' incubation at 37°C. was recorded on a 
-b-k-b  +  to 0 scale. 
Typical experiments are shown in Table IV, which  reveals that the encapsu- 
lated,  glossy variants are extremely  susceptible  to phagocytosis and fail to 
survive in the blood; on the other hand,  the matt variants are resistant.  In 
the  presence  of  homologous  anti-M  serum  these  matt  variants  become  as 
susceptible as the glossy variants.  When hyaluronidase is added, which keeps 
the streptococci from regenerating their capsules throughout  the 3  hour  ex- 
perimental period, it can be noted that the decapsulated matt variants retain 
their resistance to the bacteriostatic action of the blood.  The decapsulated 
as well as the encapsulated matt variants become as susceptible on inclusion 
of anti-!V[ serum in the system as the glossy variants. 
It appears from the findings of these in vitro experiments that the M  sub- 
stance is far more important than the hyaluronic acid capsule in causing the 
streptococci to resist the phagocytic and bacteriostatic effect of the blood, but 
there was a definite indication from the opsonic index experiments that removal 
of the capsule enhanced the phagocytic effect of the leukocytes. 
Demonstration of Protective Capacity of Crude Bovine Testicular ttyaluronidase 
against Group C Streptococcal Infection in Mice.--Although the r61e played by 332  GROUP  A  STREPTOCOCCUS  INFECTIONS 
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the  M  protein of the streptococcal cell in  resisting the phagocytic action  of 
leukocytes contained in human blood appeared clearly defined in the in ~ro 
experiments,  the  effect of the  capsule  was  still  not  well  understood.  We, 
therefore, attempted to study the problem in an in ~ivo system employing the 
mouse as a  test animal. 
To make certain that the preparation containing hyaluronidase was active in 
the in ~vo  system selected,  the  bovine testicular  extract was  tested for its 
effect in protecting mice against infection with group C streptococci.  Previous 
workers, with one exception, obtained good protection in similar experiments. 
The procedure employed was essentially the same as that described by Kass and Seastone 
(8) for protection experiments with group A streptococci.  Mice  were inoculated intraperi- 
toneally with tenfold serial dilutions of 4 hour broth cultures of encapsulated group C strep- 
tococci, strain  D181.  The number of streptococci inoculated were calculated by pouring 
rabbit blood agar plates and the colony counts were 26 in the 10  -7 dilution and 240 in the 10  ~ 
dilution.  Treatment  with 0.5 cc. crude bovine tesficular extract containing 100 viscosity- 
reducing units was started 2 hours later.  Injections of enzyme were given intraperitoneally 
every 2 hours for the first 12 hours, every 4 hours during the next 36 hours, and every 12 
hours for the last 48 hours; a total of 19 injections. 
In Table V  are illustrated  the results of the protective influence of crude 
bovine testicular hyaluronidase  on mice infected with group  C  streptococci. 
The enzyme protected all mice completely against 1,000 ~r.L.D. and some of the 
mice against even 100,000 ~.LD.  A control group of mice treated with enzyme 
inactivated by heating to 50°C. for 30 minutes died as rapidly as the untreated 
virulence controls.  These findings  are remarkably similar to those of Hirst 
(4), who employed leech extract as a  source of enzyme. 
Method of Demonstrating Mouse Protection against Group A  Streptococci with 
ltyaluronidase.--Since  crude  testicular  hyaluronidase  was  thus  found  to  be 
effective  in  protecting  mice  against  infections  with  encapsulated group  C 
streptococci (Table V), experiments were undertaken in an attempt to also ob- 
tain protection in mice with encapsulated group A streptococci.  In the studies 
of Kass and Seastone (8), who were successful in such experiments, it was noted 
that  the  final  dilutions  of  the  streptococci were  made  in  testicular  extract 
and allowed to remain for 5 minutes at room temperature before injection of 
the mixture; streptococci used for the controls, however, were diluted in plain 
broth.  Blundell  (6)  had previously shown that simultaneous injections of a 
mixture of bovine testicular extract and streptococci, followed by treatment 
with the enzyme, provided the greatest delay in the time of death as compared 
with untreated control mice.  These observations suggested an explanation for 
the fact that  we had earlier failed to obtain any protection of mice against 
group A streptococci since 2 hours had elapsed before enzyme treatment was 
started. 
The effect of giving the hyaluronidase simultaneously with the streptococci 334  GROUP  A  sTREPTOCOCCUS IN~FECTIONS 
by diluting the bacteria in the testicular extract was compared with the effect 
of delaying treatment  by diluting the streptococci in plain broth and giving 
the first injection of enzyme 2 hours later.  The results of such an experiment 
are shown  in Table VI.  Encapsulated  group A  type  14 streptococci, strain 
$23,  were employed.  The  colony count  in the  10  -7 dilution was  19 colonies 
and in the 10  -8 dilution, 2 colonies.  The treatment schedule was the same as 
that  used against group  C  streptococci,  except where  earlier treatment  was 
TABLE V 
Demonstration of Protective Activity of Crude Testicular Hyaluronidase 
Mouse Protection against Group C Streptococci 
Treatment  of mice 
Unheated testicular hyaluronidase 
Heated testicular hyaluronidase* 
Untreated virulence controls 
Culture of streptococci,  strain D18I 
10 -2  10-#  10-*  10-s  10-~  10-~ 
D1  D2  S  S  S  S 
D2  S  S  S  S  S 
S  S  S  S  S  S 
S  S  S  S  S  S 
D1  D1  D1  D1 
D1  D1  D1  D2 
DI  D1  D2  D2 
D1  D2  D2  D2 
D1  D1  D1  D1  D1  D1 
D1  DI  D1  D1  D1  D2 
D1  D1  D1  D2  D2  D2 
D1  D1  D1  D2  D2  D2 
S indicates survival of one mouse for at least 2 weeks. 
D with numeral indicates death of one mouse within that number of days. 
* Hyaluronidase heated at 60°C. for 30 minutes. 
given by diluting the cultures in hyaluronidase.  In diluting the  streptococci 
in hyaluronidase, the concentration of enzyme was adjusted so that the mouse 
received the  same  amount  of enzyme  as  that  used  in  the  later  therapeutic 
doses; i.e.,  100 viscosity-reducing units. 
When the streptococci were diluted in plain broth and the mice subsequently 
treated after a  lapse of 2 hours with 19 injections of hyaluronidase for 96 hours, 
only a  slight delay in the rate of death  was  obtained as compared with  the 
untreated  controls.  In  contrast,  when  the  streptococci  were diluted  in  a 
solution  of hyaluronidase,  even  though  no  additional  treatment  was  given, 
there was some protection in the 10  -s dilution and a delay in the time of death 
in the other dilutions.  Moreover, when the mice, in addition to the first dose SIDNEY ROTHBARD  335 
TABLE VI 
Method of Demonstrating Protective Action of Crude Testieular ttyaluronidase  against Group 
A Streptococci 
Mouse Prote~m Test 
Tr~tment of mice 
Streptococci diluted  in plain 
broth 
Streptococci diluted  in solu- 
tion  of  hyaluronidase 
Untreated virulence controls 
Treated with multiple  injec- 
tions of hyaluronidase 
No additional treatment 
Treated with multiple injec- 
tions  of  hyaluronidase 
CultUre of streptococci,  strain 
$23 matt, type 14 
10~  10-1 
CG. 
10  -'e'  10-7  lO-S 
D1  D1  D1  D2  D3 
D1  D1  D1  D2  D3 
D1  D1  D1  D2  D3 
D1  D1  D2  D2  D3 
D1  D1  D2  D2  D3 
D1  D2  D2  D3  D4 
D1  D1  D2  D3  D3 
D1  D1  D2  D3  D3 
DI  D1  D2  D3  D4 
D1  D2  D3  D3  D4 
D2  D2  D3  D3  D4 
D2  D2  D4  D4  S 
D1  D2  D3  D4  D5 
D1  D2  D3  D4  D5 
D2  D2  D3  D4  D5 
D2  D2  D3  D5  S 
D2  D2  D4  D5  S 
D2  D2  D4  D5  S 
D1  D1  D4  D5  S 
D1  D2  D5  S  S 
D1  ])3  D5  S  S 
D2  D3  D6  S  S 
D2  D3  D6  S  S 
D2  D3  S  S  S 
S indicates  survival  of  one mouse for  at least  2 weeks. 
D with numeral indicates  death of  one mouse within that number of days. 
Duplicate sets  of mice treated  with hyaluronidase heated at 60°C. for  30 minutes  all  died 
at the same rate  as untreated virulence  controls, 
of hyaluronidase, were also treated with multiple injections (19 injections for 
96 hours), protection was obtained against 10 rr.L.D., with marked delay in the 
time of  death of the other mice,  as  compared with the untreated virulence 
controls. 
It is thus apparent that protection against group A  streptococcal infection 
in mice can be obtained when hyaluronidase is given concomitantly wi/th the 336  GROUP  A  STREPTOCOCCUS  INlZECTIONS 
TABLE  VII 
Combined Action of Antiserum and Crude Testicular Hyaluronidase in Prole~glng  Mir~ agalns8 
Infection with Group A Streptococd 
Mouse Protection Te~s 
Antiserum alone 
Treatment of mice 
Single injection of anti- 
serum  given  16  hrs. 
before streptococci 
Testicutar hyalur-~  Multiple  injections  of 
onidase alone  hyaluronidase* 
Both  antiserum 
and  testicular  Each given as above* 
hyaluronidase 
Antiserum  as  above: 
Control:  antise-  multiple injections of 
rum and saline  saline instead of hya- 
luronidase 
Untreated virulence controls 
Culture of streptococci, strain $23 matt, type 14 
10-1  lO-I  10-8  10  -~,  10t  10"t  10-7 
D1  D3  S  S  S  S  S 
D1  D5  S  S  S  S  S 
D1  D6  S  S  S  S  S 
D2  S  S  S  S  S  S 
D3  S  S  S  S  S  S 
D3  S  S  S  S  S  S 
D2  S  S  S  S 
D3  S  S  S  S 
D3  S  S  S  S 
D3  S  S  S  S 
S  S  S  S  S 
S  S  S  S  S 
D1  D2  S  S 
D1  D5  S  S 
DI  S  S  S 
D2  S  S  S 
D2  S  S  S 
D2  S  S  S 
D3  D3  D7  S 
D3  D3  S  S 
D3  D3  S  S 
D3  D3  S  S 
D3  D3  S  S 
D3  D4  S  S 
10-s 
D1  D1  DI  D1  D2  D2  1)2 
D1  D1  D1  D1  D2  D2  D4 
D1  D1  D1  D2  D2  D2  D4 
D1  D1  D1  D2  D2  ]:)2  D4 
D1  D1  D2  D2  D2  D2  D5 
D!  D1  D2  D2  D2  D4  S 
S indicates survival of one mouse for at least 2 weeks. 
D with numeral indicates death of one mouse within that number of days. 
* Streptococci used for inoculation of these mice were diluted in hyaluronidase. 
streptococci  and followed by additional treatment with the enzyme, but not if 
the streptococci  are diluted in broth and injected into mice, followed 2 hours 
later by treatment with hyaluronidase. stumpy ROX~B~aU~  337 
Combined Effect  of Anti-M Serum  and ttyaluronidase  in  Mouse Protection 
against Group A Streptococci.--Having  demonstrated a method by which  some 
protection of mice against encapsulated group A streptococci can be obtained 
by using hyaluronidase, thus confirming the work of Kass and Sea.stone (8), the 
protective effect of type-specific anti-M  serum was  compared  with  that  of 
hyaluronidase; and the combined effect of these 2 agents was also investigated. 
The method of treatment, which was demonstrated  as being most effective  in the preceding 
~xperiment (Table VI), was used.  Five groups of mice were selected and each treated in a 
different manner.  The first group was injected intraperitoneaUy with 0.5 cc. type-specific 
antiserum 16 hours prior to intraperitoneal inoculation with the streptococci, and no further 
treatment was given.  The second  group was inoculated with streptococci diluted in hyaluroni- 
dase and these mice were further treated with multiple injections of this substance as in the 
preceding experiment (Table VI).  The third group received the combined treatment of the 
first two groups; i.e., the mice received antiserum, were inoculated with streptococci diluted in 
hyaluronidase, and were further treated with multiple injections of the enzyme.  The fourth 
group, used as a control for the effect of repeated injections, was treated with antiserum as in 
the  first group, and received multiple injections of saline instead of hyaluronidase after 
inoculation of streptococci.  The fifth group served as untreated virulence controls. 
Table  VII  summarizes  the  findings  in  this  experiment.  With  a  single 
injection of antiserum,  protection against 10,000  to 100,000  ~.L.D.  of group A 
streptococci  was  obtained.  Protection  against  10  M.LD.  was  noted  with 
hyaluronidase.  With the combination of antiserum and testicular hyaluroni- 
dase there was an additive effect affording protection against 1,000,000 ~.LD., 
as compared with the untreated virulence controls.  The control group, given 
antiserum and multiple injections of saline instead of hyaluronidase, revealed 
that there was no non-specific protective  effect from the  multiple  injections. 
The results of this experiment show  that hyaluronidase,  effective  against 
the  capsular  material,  and  type-specific anti-M  serum,  specifically directed 
against the M  substance of the streptococcal cell, each has a protective effect 
against group A streptococcal infection in mice.  These findings also illustrate 
that the anti-M serum protects against 1,000  to 10,000  times  as many ~.L.D. 
as hyaluronidase and that the combined action of these two substances provides 
greater protection for mice than either one alone. 
DISCUSSION 
The protective  effect of hyaluronidase  derived  from  various sources  has 
usually been unquestioned with regard to experimental group C streptococcal 
infections in laboratory animals, but conflicting evidence has been obtained by 
different  investigators  as  to  its  protective  action  in  group  A  streptococcal 
infections in mice.  This has led to different  concepts as to the influence of 
the hyaluronic acid capsule on the virulence of group A streptococci.  Those 
workers, notably Hirst (4), who failed to protect mice against group A  strep- 
tococcal  infections  with  hyaluronidase,  concluded  from  their  studies  that, 338  GROUP  A  S~'REI:'TOCOCCUS  INI~ECq'IONS 
unlilre  group C streptococci,  other factors  such as the M  antigen were more 
significant than the capsule in determining  the virulence and invasiveness of 
group A streptococci. 
The present work provides  an explanation  for the discrepancy between 
this  point of  view and that of Kass and Seastone (8) who, on finding some pro- 
tcction against group A  streptococcal infection in mice treated intensively 
with hyaluronidase, expressed the view that the capsules of both group A  and 
group C streptococci are responsible for the greater part of their virulence. 
Furthermore, these  workers believed  that the M  antigen might bc of  only minor 
importance,  since group A  streptococci may elaborate M  substance without 
necessarily  being virulent  for mice. 
The evidence obtained in this  study brings out the fact,  well recognized by 
all investigators, that no single  cellular component  or product of group A 
streptococci,  or indeed probably of  any microorganism, contributes  exclusively 
to the property of  virulence.  It is  also  recognized that factors  still  not known 
arc essential  to the development of virulence  for different  animal species.  As 
an  illustration,  M-containing,  encapsulated  variants freshly isolated from 
patients, although  evidently virulent  for man are usually avirulcnt for mice. 
Apparently other cellular  functions in addition to the production of capsular 
polysaccharidc or M  protein arc also  involved in the virulence  of these micro- 
organisms for mice.  However,  unless the strain elaborates the M  antigen, 
it is not virulent for either  mouse or man.  Of the known factors,  both the 
hyaluronic acid  capsule and the M  antigen of the streptococcal  cell  have been 
shown to contribute to the exhibition of virulence, and correspondingly the 
agents which lead to their  destruction contribute to the protection of mice 
against infections  with these streptococci.  Thus, it has bccn amply demon- 
strated that the matt variants which elaborate the M  substance are  virulent 
for mice and resist  phagocytosis; the glossy variants,  however, which produce 
little  or no M  substance, are avirulent  for  mice and  are  susceptible  to phagocy- 
tosis, even though both variants arc encapsulated.  This offers  substantial 
evidence that the M  substance is an important factor  in the pathogenicity of 
group A streptococci. 
In phagocytic  experiments,  on comparing  the encapsulated  streptococci 
and  streptococci decapsulated  with  hyaluronidase, it was  noted that  the 
dccapsulatcd bacteria were taken up by the leukocytes more readily and in 
larger  numbers than the encapsulated  forms.  Further evidence was provided 
that the capsule is actually concerned with virulence to a certain extent by 
demonstrating  that mice were protected against I0 X~.L.D.  of group A  strep- 
tococci by hyaluronldasc treatment. 
To obtain this  protective effect,  it was essential  to have the capsules re- 
moved  by diluting the streptococci in a solution of hyaluronidase  before 
injection  and further  to  prevent capsule regeneration  by frequent and continued smm~x Rorm3nRi~  339 
treatment with enzyme.  No protection was obtained if the streptococci  were 
diluted in broth and the multiple injections  of hyaluronidase started 2 hours 
later, because  the injected streptococci  had multiplied so many times during 
the 2 hour interval that the enzyme therapy was inadequate to permit the host 
to deal with the increased number of bacteria.  The technique of simultaneous 
injection of enzyme and streptococci explained the success of Kass and Seastone 
(8)  in obtaining protection in mice; and it is likely that other workers  also 
would have shown protective effects if such early and intensive treatment had 
been carried out. 
The protection of mice could be increased  from the 10 •.L.9.  obtained by 
enzyme therapy alone to 1,000,000 M.L.D. by the combined use of anti-M serum 
andenzyme.  A single injection of 0.5 cc. of antiserum 16 hours before inocula- 
tion Of mice was sufficient to afford almost this much protection; and previous 
work indicates that even this dose of serum was a  great excess (17).  The 
greater protection afforded by the anti-M serum emphasizes the importance of 
the M substance in virulence of group A streptococci  and is in ag/eement with 
other studies in this report  dealing  with the opsonic  index,  bacteriostatic, 
and mouse virulence experiments. 
As previously demonstrated by Ward and Lyons (18) and shown  in this 
report,  encapsulation  does  not  necessarily  exclude  phagocytosis.  In  the 
present experiments,  decapsulated streptococci  were slightly more susceptible 
to phagocytosis than those which retained their capsules.  The encapsulated 
variants were nevertheless  still highly susceptible  to phagocytosis unless  in 
addition to capsular substance they elaborated M antigen, whereas M-produc- 
ing variants were only phagocyted to a very slight extent even though they 
were decapsulated with hyaluronidase.  This suggests  that encapsulation of 
group A  streptococci  and  resistance  to  phagocytosis do  not bear  a  direct 
relation to each other. 
Though it is hazardous to generalize from these experiments  in  mice that 
the M  substance and the capsular material play similar r61es in infections in 
man, the natural host for group A  streptococci,  it  is worthy of note  that 
one test system employed was dependent upon the phagocytic leukocytes in 
normal human blood.  Both the  M  substance  and  the capsules  had anti- 
phagocytic properties  against these human leukocytes.  That the M protein 
is intimately related to virulence of streptococci  for man is further supported 
by the fact that  in  this laboratory no strain  tested  and shown to lack  M 
antigen has ever been  isolated from a  patient in the actite phase of strep- 
tococcal  infection.  In all strains tested, whenever  the M  substance  could 
not be identified with the available  type-specific  antisera, it was  possible by 
immunizing rabbits to show that the strain produced some other M substance 
not previously identified in this laboratory.  On the other hand, strains have 
been isolated from patients in the acute phase of their infection which lacked 340  GROUP  A  STREPTOCOCCUS INFECTIONS 
the capacity to produce the capsular polysaccharide;  this  is most  strikingly 
illustrated in the case of strains of serological types 4  and  22  which produce 
hyaluronidase  (19) and therefore do not develop capsules. 
On the basis of the evidence presented,  it appears that the hyaluronic acid 
capsule  is one of  the  factors  influencing  virulence  of group  A  streptococci, 
but that the M  antigen appears to be a far more important factor in determin- 
ing this property. 
SUMMARY 
Five  strains  of encapsulated  group  A  streptococci of different  serological 
types, each with a  glossy and  a  matt  variant,  were studied  to compare the 
r61es of the M  substance and the hyaluronic acid capsule in virulence of these 
microorganisms.  The results indicated that both contribute  to the virulence 
of group  A  streptococci  but  that  the  M  antigen  is  the  more  fundamental 
factor. 
Encapsulated  variants,  both glossy and matt,  were slightly less susceptible 
to phagocytosis  than  those from which  the capsule had  been removed with 
hyaluronidase.  Glossy  variants,  containing  no  M  substance,  were readily 
phagocyted;  matt,  M-containing  variants  were  resistant  to phagocytosis 
except in the presence of anti-M  serum when they became fully susceptible. 
Only  the  M-c0ntaining,  matt  strains  were  mouse-virulent.  Mice were 
protected against infections with these strains: 
(a)  By removal of the capsule with hyaluronldase,  which resulted  in  slight 
protection,  but  only  against  10 M.L.D.  Early  and  intensive  treatment  was 
required  to  produce  this  effect; i.e.,  simultaneous  injection  of  enzyme  and 
streptococci followed by prolonged enzyme therapy. 
(b)  By a  single injection of anti-M  serum administered  the day before in- 
oculation  of  the  streptococci,  which  resulted  in  protection  against  100,000 
M.L.D. 
(c)  By combined use of enzyme and anti-M serum, an additive effect of the 
two protective agents occurred, which resulted in protection  against  1,000,000 
M.LD. 
The author wishes to thank Miss Grace Vanderhoff for technical assistance. 
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EXPLANATION OF PLATES 
These photographs were made by Mr. Joseph B. Haulenbeek. 
PLATE 13 
All preparations made with India ink; 3½ hour broth cultures of group A strep- 
tococci employed.  X 1500. 
FIo. 1. Capsule of glossy variant of type 1 (strain T1). 
FIG. 2.  Capsule of matt variant of type 1 (strain T1). 
FIG. 3.  Capsule of glossy variant of type 3 (strain T3). 
FIG. 4.  Capsule of matt variant of type 3 (strain T3). 
FIG. 5.  Capsule of glossy variant of type 12 (strain NYS). 
FIG. 6.  Capsule of matt variant of type 12 (strain N¥5). THE JOURNAL OF EXPERIMENTAL MEDICINE  VOL. 88  PLATE 13 
(Rothbard:  Group A streptococcus infections) :PLATE 14 
FIG. 7.  Capsule of glossy variant of type 14 (strain $23). 
FIG. 8.  Capsule of matt variant of type 14 (strain $23). 
FIG. 9.  Capsule of glossy variant of type 19 (strain T19). 
FIG. 10.  Capsule of matt variant of type 19 (strain T19). 
FIG. 11.  Decapsulated glossy variant of type 14 (strain  $23); 3 minutes after addi- 
tion of bovine testicular extract. 
FIG. 12.  Decapsulated matt variant of type 14 (strain $23); 3 minutes after addi- 
tion of bovine testicular  extract. THE JOURNAL OF EXPERIMENTAL MEDICINE  VOL. 88  PLATE 14 
(Rothbard:  Group A streptococcus infections) PLATE 15 
Films stained with Wright and Giemsa solution.  These are representative speci- 
mens obtained from phagocytic experiment shown in Table III.  ×  1500. 
FIc. 13.  Capsulated  matt variant of group A streptococci,  type 14,  (strain $23) 
not phagocyted by polymorphonuclear  leukocyte. 
FIG. 14.  Decapsulated matt variant of group A streptococci,  type 14, (strain $23) 
also  not phagocyted by polymorphonuclear leukocytes.  Bovine testicular extract 
employed in system to remove streptococcus  capsule. 
FIC. 15.  Capsulated  glossy variant of group A streptococci,  type 14,  (strain $23) 
being  phagocyted  by  polymorphonuclear  leukocyte.  Note  phagocytosis  despite 
presence of capsule. 
FIO. 16.  Decapsulated  glossy  variant of group A  streptococci,  type  14,  (strain 
$23) being phagocyted by polymorphonuclear  leukocytes.  Bovine testicular extract 
employed in  system to remove streptococcus  capsule.  Note increased  number of 
decapsulated streptococci being  phagocyted as compared with encapsulated strep- 
tococci shown in Fig. 15. THE JOURNAL OF EXPERIMENTAL MEDICINE  VOL. 88  PLATE iS 
(Rothbard:  Group A streptococcus infections) 